Dechra Pharmaceuticals trading in line after first quarter

Dechra Pharmaceuticals updated the market on its trading on Tuesday, reporting that performance in its first quarter was in line with management expectations.

The FTSE 250 company said it saw continued year-on-year growth in both its EU pharmaceuticals and North America pharmaceuticals operations, as its shareholders gathered in London for the annual general meeting.

It said it was “confident” in achieving its expectations for the current financial year, and in the

continued out-performance of the markets in which it operated.

“We remain confident that Dechra and its proven strategy is well placed to sustain growth,” the board said in its statement.

Dechra said it would announce its interim results for the six months ended 31 December on 25 February.

In a separate announcement on Tuesday, Dechra Pharmaceuticals confirmed the acquisition of the entire share capital of Laboratórios Vencofarma do Brasil (Venco).